Cargando…
VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension
BACKGROUND: Pulmonary Arterial Hypertension (PAH) remains a therapeutic challenge, and the search continues for more effective drugs and drug combinations. We recently reported that deletion of the vasoactive intestinal peptide (VIP) gene caused the spontaneous expression of a PH phenotype that was...
Autores principales: | Hamidi, Sayyed A, Lin, Richard Z, Szema, Anthony M, Lyubsky, Sergey, Jiang, Ya Ping, Said, Sami I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210095/ https://www.ncbi.nlm.nih.gov/pubmed/22029879 http://dx.doi.org/10.1186/1465-9921-12-141 |
Ejemplares similares
-
VIP Gene Deletion in Mice Causes Cardiomyopathy Associated with Upregulation of Heart Failure Genes
por: Szema, Anthony M., et al.
Publicado: (2013) -
VIP Regulates the Development & Proliferation of Treg in vivo in spleen
por: Szema, Anthony M, et al.
Publicado: (2011) -
Vasoactive Intestinal Peptide Knockout (VIP KO) mouse model of sulfite-sensitive asthma: up-regulation of novel lung carbonyl reductase
por: Szema, Anthony M, et al.
Publicado: (2011) -
NFATc3 and VIP in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease
por: Szema, Anthony M., et al.
Publicado: (2017) -
Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension
por: Droste, Annette S, et al.
Publicado: (2009)